

CSE: MDM

FSE: 2M0

OTCQX: MRPHF

## News Release

February 21, 2018, Kelowna, BC

### **Marapharm Ventures Inc. Announces Listing of Warrants for Trading on the CSE**

Marapharm Ventures Inc. (“Marapharm”) is pleased to announce that the CSE (the “Canadian Securities Exchange”) has approved the listing for trading its share purchase warrants (the “Warrant”).

There are currently 43,749,053 Warrants issued and outstanding. Each Warrant entitles the holder to purchase one common share of the Company with an exercise price of \$2.90 per share until January 31, 2021.

The CSE has informed the Company that the “unrestricted” Warrants will begin trading today, Wednesday February 21, 2018, at the opening of the CSE on under the symbol “MDM.WT”.

On November 17, 2017, the Company reported that 8,000,000 Warrants were subscribed for by Insiders of the Company.

“We feel that this alternative security will encourage share price speculation and offer alternative liquidity.” Linda Sampson CEO.

ABOUT MARAPHARM VENTURES INC.

[www.marapharm.com](http://www.marapharm.com)

Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded

to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.

FOR FURTHER INFORMATION:

[www.marapharm.com](http://www.marapharm.com) or Linda Sampson, CEO 778-583-4476 email [info@marapharm.com](mailto:info@marapharm.com)

SOCIAL MEDIA:

Facebook: [facebook.com/marapharm](https://facebook.com/marapharm)

Twitter: [twitter.com/marapharm](https://twitter.com/marapharm) Web

Program: [marapharm.tv](http://marapharm.tv)

STOCK EXCHANGES:

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

MARIJUANA INDUSTRY INVOLVEMENT:

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework

enacted by the applicable state in which they operate.

Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm's ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm's business is conducted in a manner consistent with state law and is in compliance with licensing requirements.

Copies of licenses are posted on Marapharm's website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.

#### FORWARD - LOOKING STATEMENTS:

Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe”, and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

